Title : AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms.

Pub. Date : 2021 Sep

PMID : 34396051






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Consistently, the AXL inhibitor bemcentinib exerted additive effects with ruxolitinib via impaired STAT3, STAT5, and AKT signaling. bemcentinib signal transducer and activator of transcription 5A Homo sapiens
2 Consistently, the AXL inhibitor bemcentinib exerted additive effects with ruxolitinib via impaired STAT3, STAT5, and AKT signaling. ruxolitinib signal transducer and activator of transcription 5A Homo sapiens